Three Repair Mechanisms, One Recurring Result

The short version

Carolina Peptide reads three research peptides against a single organizing question: what actually happens when tissue — skin, tendon, gut lining, or blood-vessel wall — is asked to repair itself faster than it normally would? The three compounds here approach that question from different angles. GLOW is a three-peptide combination aimed mostly at skin and connective tissue. KPV is a small tripeptide studied almost entirely in gut-inflammation models. TB-500 — the lead compound on this desk — is a synthetic fragment of a cell-migration protein studied across tendon, wound, cardiac, and even stroke models.

None of these three is an FDA-approved medicine. Two of the three components in GLOW, and TB-500 itself, are prohibited in tested sport. All of the human safety data behind this whole page fits inside a single 40-person trial. This desk reports what was actually measured — species, sample size, dose, and effect size — and turns none of it into a recommendation for a person to take anything.

Why these three sit together

The frame for this desk is soft-tissue and connective-tissue repair research — how peptide signaling touches the matrix (collagen, elastin, extracellular scaffolding), the vasculature that feeds a healing wound, and the cell-migration machinery that closes a gap in tissue. TB-500 is the anchor: as the actin-binding fragment of thymosin beta-4, it sits at the center of the cell-migration story, and its parent protein's data set — cardiac repair, corneal and dermal healing, even a stroke dose-response study — is the largest and most varied of the three ^{[1][11][15][16]}. GLOW borrows TB-500 for exactly this reason, pairing it with BPC-157's angiogenic signaling and GHK-Cu's collagen-synthesis effect, on the theory that matrix, vasculature, and migration are three legs of the same repair stool ^[1]. KPV sits at the edge of the frame: its repair mechanism is anti-inflammatory rather than structural, and its tissue of interest is the gut mucosa rather than skin or tendon, but the underlying logic — calm the inflammatory signal, let the tissue's own repair program run — is the same category of question.

Read individually or as a set, GLOW, KPV, and TB-500 map a spectrum from matrix-and-vessel repair to gut-lining repair to whole-body cell-migration repair.

What are research peptides?

Peptides are short chains of amino acids — smaller than proteins, often just a handful of residues (KPV is three; TB-500's fragment is seven; GHK-Cu's backbone is three). Compounds in this category are studied because a fragment or analog of a natural repair signal can be synthesized, dosed precisely in a lab model, and measured against a control. That is different from a drug being approved: synthesis and preclinical study are not the same as regulatory approval, and none of GLOW's three constituents, KPV, or TB-500 has FDA approval for any indication. Some have gone further than others: TB-500's parent protein has one completed human Phase 1 safety trial (n=40) ^[13]; BPC-157 (a GLOW constituent) has three small human pilot studies ^[2]; KPV has none. This desk reports that gradient explicitly rather than treating "peptide" as a single evidence tier.

How this desk reads the evidence

Every claim on this desk carries three data points where the source reports them: the model (species or cell line), the sample size or dose range, and the effect size — a percentage, a hazard figure, an mg/kg, a fold-change. A 2026 Sports Medicine review that names BPC-157, TB-500, and GHK-Cu together concludes that this class of compound shows favorable tissue-repair outcomes in animal models but that rigorous human safety data remain scarce, with real potential for harm outside regulated settings ^[1]. That is the honest baseline this desk starts from — encouraging preclinical mechanism, thin human evidence — and every compound page is written to make clear exactly where the evidence for that specific peptide sits on that spectrum, compound by compound, study by study.